^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TYRA-300

    i
    Other names: TYRA-300
    Company:
    Tyra Biosci
    Drug class:
    FGFR3 inhibitor
    Related drugs:
    2ms
    Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia. (PubMed, J Med Chem)
    The pan-FGFR inhibitor erdafitinib was approved for the treatment of mUC with FGFR3 alterations but is limited due to FGFR isoform off-target toxicities and the development of on-target gatekeeper resistance mutations. TYRA-300 (22) was conceived using a structure-based approach as a potent FGFR3-selective inhibitor to avoid the toxicities associated with inhibition of FGFR1, FGFR2, and FGFR4, and to be agnostic for the FGFR3 gatekeeper mutations. TYRA-300 is being evaluated in a Phase 1 clinical trial in urothelial cancers and solid tumors, with intention to initiate Phase 2 studies in urothelial cancers and achondroplasia.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR4 (Fibroblast growth factor receptor 4)
    |
    FGFR2 mutation • FGFR3 mutation • FGFR mutation • FGFR3 G380R
    |
    Balversa (erdafitinib) • TYRA-300
    8ms
    A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants (clinicaltrials.gov)
    P1, N=60, Recruiting, Tyra Biosciences, Inc | N=36 --> 60 | Trial primary completion date: Jan 2024 --> May 2024
    Enrollment change • Trial primary completion date
    |
    TYRA-300
    11ms
    A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants (clinicaltrials.gov)
    P1, N=36, Recruiting, Tyra Biosciences, Inc
    Trial completion date • Trial primary completion date
    |
    TYRA-300
    almost1year
    A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants (clinicaltrials.gov)
    P1, N=36, Recruiting, Tyra Biosciences, Inc | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TYRA-300